西安诺和达生物科技有限公司
+86 13662665103 Mon–Fri, 09:00–18:00 GMT+8 Contact Us sales@nhdbio.com
Lot-document scope confirmed before quotation · Research use only
  • Specification Review
  • Lot Documents on Request
  • Business Support · Xi’an
  • Destination Eligibility Confirmed
西安诺和达生物科技有限公司

Quote list

Review quantities before sending your request.

View full quote listContinue browsing productsThis is an enquiry list, not a checkout. No payment is taken.
 Request an Account

Research & insights

CJC-1295 With DAC: Albumin Binding, Identity Controls and FDA Safety Context

By NHD Technical TeamPublished Updated Oct 13, 2026
Editorial comic illustration: CJC-1295 With DAC. Conceptual cover, not experimental imagery.

For CJC-1295 with DAC, the albumin-reactive group is not a branding detail. It changes persistence, analytical behavior and the relevance of the published human data.

What the record shows

  • With-DAC and without-DAC materials should remain separate product families.
  • FDA flags immunogenicity, peptide-impurity and API-characterization concerns.
  • A mass result alone may not fully characterize reactive or albumin-associated species.
Scientist reviewing pulsatile growth-hormone and IGF-1 research data
Original editorial illustration used to identify the research theme. It does not depict a catalog lot, approved drug, assay result or clinical use.

The identity and evidence boundary

The certificate should identify the exact sequence, DAC-related modification, molecular form and analytical approach. Generic “CJC purity” language is not enough to distinguish the long-acting material.

Defining featureDrug-affinity-complex group designed for albumin binding
Published half-life5.8–8.1 days in the early human study
Current FDA contextLimited clinical data and reported serious adverse events

What belongs in the material record

Evidence copy should pair the early pharmacodynamic findings with current FDA safety language. Neither source validates a particular catalog lot.

Editorial rule

Use the exact intervention name, model, population and endpoint from the cited record. Do not convert an association, mechanism, animal result, approved finished-drug record or analytical test into a claim about an unrelated catalog lot.

FDA source scope: the FDA bulk-safety summary lists “CJC-1295” generically and does not resolve DAC versus without-DAC in that row. It should not be used alone as form-specific causality evidence.

Sources & editorial method

The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.

6 linked records are listed in the references below. Read the editorial and AI-assistance policy.

How to interpret this article

Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.

Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.

Primary records and authoritative sources

  1. Prolonged stimulation of GH and IGF-I secretion by CJC-1295Teichman SL, et al. J Clin Endocrinol Metab. 2006. PMID 16352683.
  2. Pulsatile GH secretion persists during CJC-1295 stimulationIonescu M, Frohman LA. J Clin Endocrinol Metab. 2006. PMID 17018654.
  3. Certain Bulk Drug Substances That May Present Significant Safety RisksU.S. FDA. Current compounding safety-information page.
  4. ICH Q2(R2): Validation of Analytical ProceduresOfficial analytical-validation framework; not evidence that a specific catalog lot has been tested.
  5. ICH Q14: Analytical Procedure DevelopmentOfficial analytical-development framework; included as general method guidance only.
  6. CJC-1295 albumin bioconjugation and receptor activityCJC-1295 albumin bioconjugation and receptor activity
Research pathways

Continue with structured records

Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.

Related evidence recordsFilter the literature database by product familyCJC-1295: DAC vs No DACOpen the reviewed comparisonResearch material glossaryDefine analytical, identity and evidence terms

Editorial source check: NHD evidence editorial workflow · 2026-08-28

On this page 7 sections

Keep reading

All articles
CJC-1295 DAC editorial illustration

CJC-1295 With DAC in Healthy Adults: GH, IGF-1 and Half-Life Data

Read article
Planning Peptide Aliquots for Three Experiments

Planning Peptide Aliquots for Three Experiments

Read article
Laboratory Handover: Help the Next Colleague Resume the Work

Laboratory Handover: Help the Next Colleague Resume the Work

Read article

CJC-1295 with DAC: why does albumin binding matter?

DAC-related modification lets CJC-1295 bind to albumin. Albumin is an abundant protein in blood, and this design is related to how long the material lasts in the body.

First, distinguish with DAC from without DAC

Names with and without DAC in the catalog must all be kept complete. Seeing the words CJC-1295 does not mean results from a study with DAC apply to every record with the same name.

DAC can first be understood as a modification design used to connect to a related carrier protein. It is not an ordinary ingredient mixed with the peptide.

What did the original design study observe?

The original study in 2005 discussed a designed GHRH-related peptide binding to albumin and examined its receptor activity and lasting effects in the corresponding experiments. The authors described using the free sulfhydryl at the Cys34 position of albumin for bioconjugation.

This explains why the linking design is worth studying, but the specific structure, reactions, and function of the material still need to be confirmed by the original methods. You cannot infer everything for all batches from the name.

Albumin binding and receptor action are not the same step

Binding to albumin mainly involves the design for distribution and duration in the body; how the peptide affects related receptors is a separate functional question. Research needs to examine both, not just confirm that binding succeeded.

A teaching diagram can arrange “modified peptide — binds to albumin — observe receptor and time-related readouts” into three steps, but it is not a human time curve.

If the half-life is long, why can it still not represent all results?

Half-life describes the time scale for the related quantity to decrease by half. It does not automatically mean that the functional response lasts the same amount of time, and it is not the shelf life of the product in the vial.

Hormone readouts in human pharmacology studies also require looking at the population, the comparison group, and the measurement schedule. The mechanism of albumin binding alone cannot prove all intended uses.

How can name confusion be avoided when requesting a quote?

Write CJC-1295 with DAC, and include the complete identity and documentation requirements that need to be checked. If other peptides or mixtures are also involved, list their components and specifications separately. After seeing a paper, first check the study material, then compare it with the catalog material.

Confirm the three concepts separately
DAC and albumin bindingQuestion it answers: What the related linking design is
Receptor activityQuestion it answers: What function the research system measured
Half-lifeQuestion it answers: How the measured related quantity changes over time
Teaching summary. Check the explanation and original sources; this is not a to-scale molecular model or a product test result.
Confirm the three concepts separately
ConceptQuestion it answers
DAC and albumin bindingWhat the related linking design is
Receptor activityWhat function the research system measured
Half-lifeHow the measured related quantity changes over time

What time scale did the human pharmacokinetic study measure?

A 2006 pharmacology study in healthy adults estimated a CJC-1295 half-life of 5.8–8.1 days. This is an in-body pharmacokinetic measure, not vial stability or a measurement of a no-DAC material. Read it alongside the 2005 albumin-conjugation study to separate the mechanism from the measured time scale.

Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults · 2006

Original sources and further reading

Sources checked on 2026-10-13. Findings apply to the models and materials studied. Batch quality requires records for the actual batch.

Related research materials

CJC-1295 (with DAC)View material identity, specifications, and packaging; documentation needs can be raised with an inquiry.

Ask about specifications, quantity, and required documentation